Ann: Trial Met Primary & Exceeded Secondary Endpoint Expectations, page-193

@arjay

I think you will find that any mention of none dilutive funding relates to 1102 for ms as in none dilutive grant funding

Point me to where Diamond has ever mention no more CR

I don't recall any mention of this

Not having a go arjay but unless we get notice of partnering within the next 6 months I don't see how we are going to avoid a CR even then we won't receive any cash before we are due to start our 2b for DMD

but a deal of sareptas magnitude may get us a none dilutive deal from a bank untill funds from any partner were in

I still think the best deal would to go 50 - 50 world wide with DMD

On saying that I would not want to see a deal brokered for any less than the Roche, Sarepta deal and I don't care what type of antisense we have

Our ph2 results have spoken

Sareptas ph2 is not yet complete and double blinded so Roche have gone in big on pre clinical data or animal studies on mice, wow
their trial Is a combination pH 1 / 2 and could in actual fact fall over

This is the closest comparison we can make with regards to our valuation in any partnering deal anything less would have to be a joke

Much the same as our sp today a joke

Today we broke that 6.4c support

Hmmm

Let's not

see how we go

Let's

See where we go